Vitamin c and immunotherapy combo tested in lung cancer window trial
NCT ID NCT06083454
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 33 times
Summary
This early-phase trial tested whether combining high-dose vitamin C with the immunotherapy drug durvalumab could boost the immune system's attack on non-small cell lung cancer before surgery. Only one person took part before the study was stopped. The main goal was to measure immune cell changes in the tumor, not to provide a cure or long-term treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.